DK1327440T5 - Orale pr parater med gunstige nedbrydningsegenskaber - Google Patents
Orale pr parater med gunstige nedbrydningsegenskaberInfo
- Publication number
- DK1327440T5 DK1327440T5 DK01965637T DK01965637T DK1327440T5 DK 1327440 T5 DK1327440 T5 DK 1327440T5 DK 01965637 T DK01965637 T DK 01965637T DK 01965637 T DK01965637 T DK 01965637T DK 1327440 T5 DK1327440 T5 DK 1327440T5
- Authority
- DK
- Denmark
- Prior art keywords
- water
- carmellose
- sodium
- disintegrant
- granule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000288234 | 2000-09-22 | ||
PCT/JP2001/007983 WO2002024166A1 (fr) | 2000-09-22 | 2001-09-14 | Preparations orales dotees de bonnes caracteristiques de desagregation |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1327440T3 DK1327440T3 (da) | 2009-06-08 |
DK1327440T5 true DK1327440T5 (da) | 2009-09-07 |
Family
ID=18771855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01965637T DK1327440T5 (da) | 2000-09-22 | 2001-09-14 | Orale pr parater med gunstige nedbrydningsegenskaber |
Country Status (11)
Country | Link |
---|---|
US (1) | US7727553B2 (de) |
EP (2) | EP1974724A3 (de) |
JP (1) | JP4868695B2 (de) |
AT (1) | ATE431136T1 (de) |
AU (1) | AU2001286237A1 (de) |
CA (2) | CA2824077C (de) |
DE (1) | DE60138722D1 (de) |
DK (1) | DK1327440T5 (de) |
ES (1) | ES2325764T3 (de) |
TW (2) | TWI289062B (de) |
WO (1) | WO2002024166A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295061A1 (de) * | 2002-08-22 | 2011-03-16 | Dainippon Sumitomo Pharma Co., Ltd. | Verbindung zur Behanlung von Schizophrenie |
SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
JP4624261B2 (ja) | 2003-06-23 | 2011-02-02 | 大日本住友製薬株式会社 | 老人性痴呆症治療剤 |
US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
JP5219508B2 (ja) | 2005-05-18 | 2013-06-26 | 大日本住友製薬株式会社 | ドロキシドパを含有する安定な錠剤 |
EP2422783B1 (de) * | 2005-05-26 | 2015-04-08 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmazeutische Zusammensetzung |
CN101198331B (zh) * | 2005-06-13 | 2012-05-02 | 大日本住友制药株式会社 | 增溶化制剂 |
KR101465803B1 (ko) * | 2005-08-10 | 2014-11-26 | 시오노기세이야쿠가부시키가이샤 | 구강내 붕괴 정제 |
EP1927347A4 (de) * | 2005-08-10 | 2011-10-12 | Shionogi & Co | Mittel zur verringerung von bitterkeit |
EP1973531A2 (de) * | 2006-01-02 | 2008-10-01 | Rubicon Research Private Limited | Pharmazeutische zusammensetzungen |
PE20081891A1 (es) * | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
CA2704209C (en) | 2007-10-31 | 2017-02-28 | Mcneil-Ppc, Inc. | Orally disintegrative dosage form |
CN101945657B (zh) | 2008-02-11 | 2015-04-22 | 大日本住友制药株式会社 | 具有改善的溶出性的片剂 |
WO2009151072A1 (ja) | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
JP5714492B2 (ja) * | 2008-09-17 | 2015-05-07 | マイラン インコーポレイテッド | 粒状体、それらの調製方法、およびそれらを含む医薬品 |
US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
US9433620B2 (en) * | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
WO2013140324A1 (en) | 2012-03-21 | 2013-09-26 | Koninklijke Philips N.V. | Method and apparatus for providing a visual representation of sleep quality based on ecg signals |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9511028B2 (en) * | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
JP6007169B2 (ja) * | 2012-11-30 | 2016-10-12 | 大原薬品工業株式会社 | アリピプラゾール無水物を含有する固形製剤の製造方法 |
WO2014090386A1 (en) | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
JP6037824B2 (ja) * | 2012-12-28 | 2016-12-07 | ライオン株式会社 | エトドラク含有固形製剤 |
JP2014129238A (ja) * | 2012-12-28 | 2014-07-10 | Lion Corp | エトドラク含有固形製剤 |
WO2015105992A1 (en) | 2014-01-10 | 2015-07-16 | Mcneil-Ppc, Inc. | Process for making tablet using radiofrequency and lossy coated particles |
WO2016012898A1 (en) | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
WO2016139683A2 (en) * | 2015-03-05 | 2016-09-09 | Jubilant Generics Limited | Pharmaceutical compositions of lurasidone and process for preparing the same |
EP3892263A1 (de) | 2016-03-25 | 2021-10-13 | Universiteit Gent | Orale darreichungsform |
US10966928B2 (en) | 2016-03-25 | 2021-04-06 | Universiteit Gent | Oral dosage form |
AU2017244984A1 (en) * | 2016-03-31 | 2018-11-01 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
US20210290535A1 (en) * | 2016-08-31 | 2021-09-23 | Takuma TSUZUKU | Aqueous suspension preparation |
US11260055B2 (en) | 2017-01-11 | 2022-03-01 | Piramal Enterprises Limited | Oral pharmaceutical composition of lurasidone and preparation thereof |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
AT17300U3 (de) * | 2020-12-03 | 2022-02-15 | G L Pharma Gmbh | Feste orale pharmazeutische Zusammensetzung |
TW202333719A (zh) * | 2021-11-04 | 2023-09-01 | 大陸商上海博志研新藥物技術有限公司 | 鹽酸魯拉西酮口溶膜組合物、其製備方法及用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61148114A (ja) * | 1984-11-15 | 1986-07-05 | Teijin Ltd | ニフエジピンの顆粒剤 |
JP2800953B2 (ja) * | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
JPH04305526A (ja) * | 1991-03-28 | 1992-10-28 | Morishita Roussel Kk | 薬剤組成物 |
ZA939565B (en) | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
US5811120A (en) | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
EP0839526A3 (de) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften |
TW482675B (en) * | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
NZ505123A (en) * | 1997-12-19 | 2003-07-25 | Smithkline Beecham Corp | Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
JP4438121B2 (ja) * | 1998-04-27 | 2010-03-24 | 大正製薬株式会社 | 口腔内速崩錠及びその製造方法 |
KR100267576B1 (ko) * | 1998-07-25 | 2000-11-01 | 허계성 | 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법 |
JP2000086503A (ja) * | 1998-09-07 | 2000-03-28 | Pola Chem Ind Inc | 錠剤医薬組成物 |
JP2000086509A (ja) * | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
-
2001
- 2001-09-14 DK DK01965637T patent/DK1327440T5/da active
- 2001-09-14 JP JP2002528202A patent/JP4868695B2/ja not_active Expired - Fee Related
- 2001-09-14 DE DE60138722T patent/DE60138722D1/de not_active Expired - Lifetime
- 2001-09-14 EP EP08156778A patent/EP1974724A3/de not_active Withdrawn
- 2001-09-14 ES ES01965637T patent/ES2325764T3/es not_active Expired - Lifetime
- 2001-09-14 US US10/381,036 patent/US7727553B2/en not_active Expired - Lifetime
- 2001-09-14 CA CA2824077A patent/CA2824077C/en not_active Expired - Lifetime
- 2001-09-14 AT AT01965637T patent/ATE431136T1/de not_active IP Right Cessation
- 2001-09-14 WO PCT/JP2001/007983 patent/WO2002024166A1/ja active Application Filing
- 2001-09-14 EP EP01965637A patent/EP1327440B1/de not_active Expired - Lifetime
- 2001-09-14 AU AU2001286237A patent/AU2001286237A1/en not_active Abandoned
- 2001-09-14 CA CA2424001A patent/CA2424001C/en not_active Expired - Lifetime
- 2001-09-19 TW TW090123036A patent/TWI289062B/zh not_active IP Right Cessation
- 2001-09-19 TW TW094103731A patent/TWI289063B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TWI289062B (en) | 2007-11-01 |
CA2824077C (en) | 2016-01-26 |
EP1327440A1 (de) | 2003-07-16 |
TW200524642A (en) | 2005-08-01 |
JPWO2002024166A1 (ja) | 2004-01-29 |
DK1327440T3 (da) | 2009-06-08 |
EP1974724A2 (de) | 2008-10-01 |
CA2424001C (en) | 2013-10-22 |
AU2001286237A1 (en) | 2002-04-02 |
US20040028741A1 (en) | 2004-02-12 |
TWI289063B (en) | 2007-11-01 |
ES2325764T3 (es) | 2009-09-16 |
CA2424001A1 (en) | 2003-03-20 |
CA2824077A1 (en) | 2002-03-28 |
DE60138722D1 (de) | 2009-06-25 |
WO2002024166A1 (fr) | 2002-03-28 |
EP1327440B1 (de) | 2009-05-13 |
JP4868695B2 (ja) | 2012-02-01 |
EP1327440A4 (de) | 2006-02-01 |
EP1974724A3 (de) | 2008-11-12 |
ATE431136T1 (de) | 2009-05-15 |
US7727553B2 (en) | 2010-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1327440T5 (da) | Orale pr parater med gunstige nedbrydningsegenskaber | |
EP1884242A4 (de) | Pharmazeutische zusammensetzung | |
EE05022B1 (et) | Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat | |
DK200001170A (da) | Farmaceutiske sammensætninger | |
HUP9902808A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása | |
CA2395846A1 (en) | Diazepan derivatives or salts thereof | |
DE69908626D1 (de) | Orale kombination von lufenuron und nitenpyram gegen flöhe | |
EP1738756A3 (de) | Esmolol-enthaltende Zubereitungen | |
RU96116411A (ru) | Быстро распадающаяся готовая препаративная форма трамадола или соли трамадола | |
DE60233552D1 (de) | Fenofibrattabletten | |
US20050202083A1 (en) | Storage stable tablets of fosinopril sodium | |
HUP0500842A2 (hu) | Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra | |
EP1645273A3 (de) | Neue Verwendung von (R)-(-)-2-(5-(4-Fluorophenyl)-3-Pyridylmethylaminomethyl)-Chromane und ihrer physiologisch verträglichen Salze | |
CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration | |
NO20033855D0 (no) | Fremgangsmåte ved fremstilling av farmasöytiske tabletter inneholdende paroxetinhydrokloridanhydrat | |
EP1113015A4 (de) | Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten | |
CA2443019A1 (en) | Kappa-opiate agonists for the treatment of bladder diseases | |
WO2008016165A3 (en) | Liquid preparation | |
WO2005034954A3 (en) | Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation | |
RU98114489A (ru) | СОСТАВ ИНГИБИТОРА 5α-РЕДУКТАЗЫ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ИСПОЛЬЗОВАНИЕ | |
NO20031030L (no) | Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel | |
TH45760B (th) | สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก | |
RU97119777A (ru) | Фармацевтическая таблетированная композиция противовоспалительного действия | |
WO2003004019A8 (en) | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia |